Clements DR - Search Results

1

Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.

Prokopi A, Tripp CH, Tummers B, Hornsteiner F, Spoeck S, Crawford JC, Clements DR, Efremova M, Hutter K, Bellmann L, Cappellano G, Cadilha BL, Kobold S, Boon L, Ortner D, Trajanoski Z, Chen S, de Gruijl TD, Idoyaga J, Green DR, Stoitzner P. Prokopi A, et al. Among authors: clements dr. J Immunother Cancer. 2021 Jan;9(1):e000832. doi: 10.1136/jitc-2020-000832. J Immunother Cancer. 2021. PMID: 33408092 Free PMC article.

2

Alveolar macrophages and epithelial cells: The art of living together.

Clements D, Idoyaga J. Clements D, et al. J Exp Med. 2021 Oct 4;218(10):e20211583. doi: 10.1084/jem.20211583. Epub 2021 Sep 7. J Exp Med. 2021. PMID: 34491265 Free PMC article.

3

CD301b+ monocyte-derived dendritic cells mediate resistance to radiotherapy.

Tadepalli S, Clements DR, Raquer-McKay HM, Lüdtke A, Saravanan S, Seong D, Vitek L, Richards CM, Carette JE, Mack M, Gottfried-Blackmore A, Graves EE, Idoyaga J. Tadepalli S, et al. Among authors: clements dr. J Exp Med. 2025 Jun 2;222(6):e20231717. doi: 10.1084/jem.20231717. Epub 2025 Mar 27. J Exp Med. 2025. PMID: 40146036 Free PMC article.

4

Rapid recruitment and IFN-I-mediated activation of monocytes dictate focal radiotherapy efficacy.

Tadepalli S, Clements DR, Saravanan S, Arroyo Hornero R, Lüdtke A, Blackmore B, Paulo JA, Gottfried-Blackmore A, Seong D, Park S, Chan L, Kopecky BJ, Liu Z, Ginhoux F, Lavine KJ, Murphy JP, Mack M, Graves EE, Idoyaga J. Tadepalli S, et al. Among authors: clements dr. Sci Immunol. 2023 Jun 2;8(84):eadd7446. doi: 10.1126/sciimmunol.add7446. Epub 2023 Jun 9. Sci Immunol. 2023. PMID: 37294749 Free PMC article.

5

Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy.

Kim Y, Clements DR, Sterea AM, Jang HW, Gujar SA, Lee PW. Kim Y, et al. Among authors: clements dr. Viruses. 2015 Dec 9;7(12):6506-25. doi: 10.3390/v7122953. Viruses. 2015. PMID: 26690204 Free PMC article. Review.

6

Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.

Gujar SA, Clements D, Dielschneider R, Helson E, Marcato P, Lee PW. Gujar SA, et al. Br J Cancer. 2014 Jan 7;110(1):83-93. doi: 10.1038/bjc.2013.695. Epub 2013 Nov 26. Br J Cancer. 2014. PMID: 24281006 Free PMC article.

7

Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation.

Gujar S, Dielschneider R, Clements D, Helson E, Shmulevitz M, Marcato P, Pan D, Pan LZ, Ahn DG, Alawadhi A, Lee PW. Gujar S, et al. Mol Ther. 2013 Feb;21(2):338-47. doi: 10.1038/mt.2012.228. Epub 2012 Nov 13. Mol Ther. 2013. PMID: 23299799 Free PMC article.

8

Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy.

Hill R, Rabb M, Madureira PA, Clements D, Gujar SA, Waisman DM, Giacomantonio CA, Lee PW. Hill R, et al. Cell Death Dis. 2013 Sep 5;4(9):e791. doi: 10.1038/cddis.2013.307. Cell Death Dis. 2013. PMID: 24008735 Free PMC article.

9

The NAD+ synthesizing enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) is a p53 downstream target.

Pan LZ, Ahn DG, Sharif T, Clements D, Gujar SA, Lee PW. Pan LZ, et al. Cell Cycle. 2014;13(6):1041-8. doi: 10.4161/cc.28128. Epub 2014 Feb 7. Cell Cycle. 2014. PMID: 24552824 Free PMC article.

10

Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses.

Gujar SA, Clements D, Lee PW. Gujar SA, et al. Oncoimmunology. 2014 Jan 1;3(1):e27622. doi: 10.4161/onci.27622. Epub 2014 Jan 6. Oncoimmunology. 2014. PMID: 24804161 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

50 results

Search Page

Filters